Phase I trial of vorinostat and doxorubicin in solid tumours: histone deacetylase 2 expression as a predictive marker

Pamela N. Münster, Douglas C. Marchion, Scott Thomas, +8

British Journal of Cancer

No Difference Between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients With Symptomatic Celiac Disease

Joseph A. Murray, Ciarán P. Kelly, Peter H.R. Green, +93

Gastroenterology

Difference Between LatiglutenaseVillous AtrophyClinical PresentationCeliac DiseaseMedicine +1

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Erin A. Bohula, Benjamin M. Scirica, Silvio E. Inzucchi, +564

The Lancet

ObesityMetabolic SyndromeCamellia-timi 61Diabetes ManagementDiabetes +7

Preservation of ovarian function in young women treated with neoadjuvant chemotherapy for breast cancer: A randomized trial using the GnRH agonist (triptorelin) during chemotherapy

Roohi Ismail‐Khan, S. Minton, Catrin Cox, +6

Journal of Clinical Oncology

Reproductive SciencesBreast OncologyReproductive HealthAdjuvant ChemotherapyGynecology +21

RETRACTED ARTICLE: Aurora-A is a determinant of tamoxifen sensitivity through phosphorylation of ERα in breast cancer

Xiangqian Zheng, Jian Guo, Hua Yang, +9

Oncogene

Tumor BiologySystems BiologyOncologyBreast OncologyMedicine +9

Nurse/physician collaborative practice: improving health care quality while decreasing cost.

Arianna Lassen, D M Fosbinder, S. Minton, +1

PubMed

NeonatologyHealth Care QualityPrimary CareR/o SepsisRule-out Sepsis +16

Nonlinear dobutamine pharmacokinetics in a pediatric population

William Banner, Donald D. Vernon, S. Minton, +1

Critical Care Medicine

Abstract GS3-08: Pathological complete response predicts event-free and distant disease-free survival in the I-SPY2 TRIAL

Douglas Yee, A. DeMichele, Claudine Isaacs, +74

Cancer Research

Breast OncologyDisease ProgressionCancer ManagementImmunologyPathology +17

Phase II trial of vorinostat, a histone deacetylase inhibitor to restore the hormone sensitivity to the anti-estrogen tamoxifen in patients with advanced breast cancer having failed prior aromatase inhibitor therapy

Pamela N. Münster, M. Lacevic, Mark R. Schmitt, +5

Journal of Clinical Oncology

Breast OncologyEstrogen ReceptorGynecologyPharmacotherapyHdac Inhibitor +19

Abstract GS4-01: Pooled analysis of five randomized trials investigating temporary ovarian suppression with gonadotropin-releasing hormone analogs during chemotherapy as a strategy to preserve ovarian function and fertility in premenopausal early breast cancer patients

Matteo Lambertini, HCF Moore, RCF Leonard, +18

Cancer Research

Hormonal ContraceptiveBreast OncologyFertilityReproductive HealthGynecology +19